{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T07:56:11Z","timestamp":1776412571181,"version":"3.51.2"},"reference-count":24,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T00:00:00Z","timestamp":1582934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Recombinant human growth hormone (rhGH) replacement therapy is often prescribed in patients with nonfunctioning pituitary adenoma (NFPA) or craniopharyngioma,<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To study whether rhGH therapy in patients with adult growth hormone deficiency (AGHD) increases the risk of pituitary tumor recurrence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Retrospective, observational study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>Tertiary care center.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients<\/jats:title>\n                  <jats:p>We studied 283 consecutive patients with AGHD due to NFPA or craniopharyngioma between 1995 and 2018.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Intervention<\/jats:title>\n                  <jats:p>rhGH treatment at standard doses was initiated in 123 patients (43.5%). The remaining 160 patients served as controls.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measure<\/jats:title>\n                  <jats:p>Risk of tumor recurrence in rhGH-treated and control patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In univariate analysis, recurrence of the pituitary tumor was less frequent in rhGH-treated patients (19.5%) than in controls (29.7%; hazard ratio [HR] 0.53, 95% confidence interval [CI] 0.32\u20130.86; P\u2005=\u2005.01). Multivariate Cox analysis demonstrated that the risk of tumor recurrence was associated with detection of residual disease at the baseline magnetic resonance imaging (HR 9.17; 95% CI, 4.88\u201317.22; P\u2005&amp;lt;\u2005.001) and not having performed radiotherapy (HR 16.97; 95% CI, 7.55\u201338.16; P\u2005&amp;lt;\u2005.001), while rhGH treatment was no longer associated with a lower risk of recurrence (HR 0.82; 95% CI, 0.47\u20131.44; P\u2005=\u2005.50).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We found no association between rhGH replacement and the risk of tumor recurrence in patients with AGHD caused by NFPA or craniopharyngioma. These data add to the mounting evidence that rhGH therapy has a neutral effect on the recurrence of pituitary tumors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Pr\u00e9cis<\/jats:title>\n                  <jats:p>Replacement therapy with rhGH is prescribed to patients with adult growth hormone deficiency. Our study found no increased risk of pituitary tumor recurrence.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgaa089","type":"journal-article","created":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T05:39:49Z","timestamp":1582954789000},"page":"1573-1580","source":"Crossref","is-referenced-by-count":37,"title":["Growth Hormone Therapy Does Not Increase the Risk of Craniopharyngioma and Nonfunctioning Pituitary Adenoma Recurrence"],"prefix":"10.1210","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7810-8247","authenticated-orcid":false,"given":"Marco","family":"Losa","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University Milan, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Castellino","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Internal Medicine, IRCCS San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Pagnano","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Internal Medicine, IRCCS San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Rossini","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Internal Medicine, IRCCS San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Mortini","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University Milan, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Lanzi","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Internal Medicine, IRCCS San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2020,2,29]]},"reference":[{"issue":"1","key":"2021122103581252400_CIT0001","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2265.1994.tb02452.x","article-title":"Decreased psychological well-being in adult patients with growth hormone deficiency","volume":"40","author":"Ros\u00e9n","year":"1994","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"3","key":"2021122103581252400_CIT0002","first-page":"669","article-title":"Reduced bone mineral density in patients with adult onset growth hormone deficiency","volume":"78","author":"Holmes","year":"1994","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021122103581252400_CIT0003","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12020-015-0738-z","article-title":"Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency","volume":"52","author":"Mazziotti","year":"2016","journal-title":"Endocrine."},{"issue":"11","key":"2021122103581252400_CIT0004","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1210\/jc.2016-2118","article-title":"Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline","volume":"101","author":"Fleseriu","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2021122103581252400_CIT0005","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1210\/jc.2014-3787","article-title":"Excess mortality associated with hypopituitarism in adults: a meta-analysis of observational studies","volume":"100","author":"Pappachan","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2021122103581252400_CIT0006","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1210\/jc.2011-0179","article-title":"Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline","volume":"96","author":"Molitch","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2021122103581252400_CIT0007","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1210\/jc.2008-0713","article-title":"Changing patterns of the adult growth hormone deficiency diagnosis documented in a decade-long global surveillance database","volume":"94","author":"Webb","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021122103581252400_CIT0008","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1530\/EJE-12-0807","article-title":"Prevalence of diabetes mellitus in 6050 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis","volume":"168","author":"Abs","year":"2013","journal-title":"Eur J Endocrinol."},{"issue":"11","key":"2021122103581252400_CIT0009","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1210\/jcem.86.11.8018","article-title":"Hypothalamo-pituitary surveillance imaging in hypopituitary patients receiving long-term GH replacement therapy","volume":"86","author":"Frajese","year":"2001","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2021122103581252400_CIT0010","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1530\/eje.0.1460807","article-title":"Does GH replacement therapy in adult GH-deficient patients result in recurrence or increase in size of pituitary tumours?","volume":"146","author":"Hatrick","year":"2002","journal-title":"Eur J Endocrinol."},{"issue":"5","key":"2021122103581252400_CIT0011","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/j.1365-2265.2006.02508.x","article-title":"GH replacement does not increase the risk of recurrence in patients with craniopharyngioma","volume":"64","author":"Karavitaki","year":"2006","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"2","key":"2021122103581252400_CIT0012","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1530\/EJE-07-0164","article-title":"Influence of GH substitution therapy in deficient adults on the recurrence rate of hormonally inactive pituitary adenomas: a case control study","volume":"157","author":"Buchfelder","year":"2007","journal-title":"Eur J Endocrinol."},{"issue":"3","key":"2021122103581252400_CIT0013","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2265.2008.03391.x","article-title":"GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence","volume":"70","author":"Arnold","year":"2009","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"5","key":"2021122103581252400_CIT0014","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1530\/EJE-09-0572","article-title":"Comparing progression of non-functioning pituitary adenomas in hypopituitarism patients with and without long-term GH replacement therapy","volume":"161","author":"Olsson","year":"2009","journal-title":"Eur J Endocrinol."},{"issue":"6","key":"2021122103581252400_CIT0015","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1530\/EJE-12-0077","article-title":"Tumour recurrence and enlargement in patients with craniopharyngioma with and without GH replacement therapy during more than 10 years of follow-up","volume":"166","author":"Olsson","year":"2012","journal-title":"Eur J Endocrinol."},{"issue":"2","key":"2021122103581252400_CIT0016","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s12020-018-1787-x","article-title":"Progression of pituitary tumours: impact of GH secretory status and long-term GH replacement therapy","volume":"63","author":"Gasco","year":"2019","journal-title":"Endocrine."},{"issue":"8","key":"2021122103581252400_CIT0017","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1210\/jc.2015-1764","article-title":"Tumor recurrence or regrowth in adults with nonfunctioning pituitary adenomas using GH replacement therapy","volume":"100","author":"van Varsseveld","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"2021122103581252400_CIT0018","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1530\/eje.0.148s009","article-title":"Long-term experience with GH replacement therapy: efficacy and safety","volume":"148 Suppl 2","author":"Monson","year":"2003","journal-title":"Eur J Endocrinol."},{"issue":"2","key":"2021122103581252400_CIT0019","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1530\/EJE-15-0873","article-title":"GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults","volume":"174","author":"Allen","year":"2016","journal-title":"Eur J Endocrinol."},{"issue":"2","key":"2021122103581252400_CIT0020","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1530\/eje.1.01967","article-title":"The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index","volume":"153","author":"Corneli","year":"2005","journal-title":"Eur J Endocrinol."},{"issue":"3","key":"2021122103581252400_CIT0021","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3171\/JNS\/2008\/108\/3\/0525","article-title":"Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence","volume":"108","author":"Losa","year":"2008","journal-title":"J Neurosurg."},{"issue":"5","key":"2021122103581252400_CIT0022","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.3171\/2010.11.JNS10670","article-title":"Neurosurgical treatment of craniopharyngioma in adults and children: early and long-term results in a large case series","volume":"114","author":"Mortini","year":"2011","journal-title":"J Neurosurg."},{"issue":"5","key":"2021122103581252400_CIT0023","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1530\/EJE-18-0505","article-title":"Long-term effects of growth hormone replacement therapy in childhood-onset craniopharyngioma: results of the German Craniopharyngioma Registry (HIT-Endo)","volume":"179","author":"Boekhoff","year":"2018","journal-title":"Eur J Endocrinol."},{"issue":"4","key":"2021122103581252400_CIT0024","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3171\/2016.4.PEDS16112","article-title":"Physiological growth hormone replacement and rate of recurrence of craniopharyngioma: the Genentech National Cooperative Growth Study","volume":"18","author":"Smith","year":"2016","journal-title":"J Neurosurg Pediatr."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaa089\/32717229\/dgaa089.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/5\/1573\/41828858\/jcem_105_5_1573.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/5\/1573\/41828858\/jcem_105_5_1573.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T04:02:54Z","timestamp":1640059374000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/105\/5\/1573\/5766671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,29]]},"references-count":24,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,2,29]]},"published-print":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaa089","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5]]},"published":{"date-parts":[[2020,2,29]]}}}